Orbis begins using Gefion, Denmark’s first AI supercomputer
Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation announced that Orbis has begun using Denmark’s first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds.
Health Technology Insights: WSP acquires specialist healthcare and life sciences consulting firm Lexica
Orbis is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. The company develops compounds known as nCycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features.
“Our advanced Gen platform helps us quickly create large numbers of custom-designed macrocycles with unique properties and broad medical applicability,” said Orbis CEO Morten Graugaard. “By combining this platform with Gefion’s computing power, we can extend beyond the nearly 140 billion compounds in our existing libraries to design entirely new collections of these molecules. This means we can explore an even broader range of chemical possibilities and more fully unlock the potential of macrocycles to improve healthcare.”
Health Technology Insights: PathAI and Northwestern Medicine Partner to Launch AI Pathology Platform
“Orbis’ nGen platform, which has already been used to design, synthesize and test more than 700,000 individual nCycles, is an ideal application for Gefion’s capabilities,” said Orbis Medicines Board Chair Mikael Dolsten, M.D., Ph.D. “Combining the power of this supercomputer with our in-house target nCycle data collection, generative AI, and nCycle synthesis capabilities will accelerate the development of orally available macrocycles that have the potential to disrupt the current biologics market and provide new treatment options for patients.”
“Gefion is designed to deliver AI innovation at scale through immense computing power applied to the most challenging problems,” said Dr. Nadia Carlsten, CEO of DCAI. “As a biomedical start-up with its own internal AI technology applied to drug design and the ability to generate vast data sets, Orbis is an ideal partner to demonstrate what Gefion can unlock when matched with specialist expertise.”
DCAI’s Gefion supercomputer contains 1,528 NVIDIA GPUs and is optimized for large-scale AI-driven projects. Gefion enables innovators to utilize advanced computation to accelerate discovery in various fields, including biotechnology and drug discovery. Gefion has previously been used by researchers, start-ups, and large enterprises to develop new AI models and perform simulations in weather modeling, quantum computing, and business automation.
Health Technology Insights: Myriad Genetics Reveals New Data on Precise MRD Sensitivity
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
